Fosfomycin in acute bronchopneumopathies

Area of Science:

• Infectious Diseases
• Pulmonology
• Pharmacology

Background:

• Acute bronchial and bronchopulmonary processes are common respiratory infections.
• Bacterial pathogens such as Streptococcus pneumoniae and Klebsiella frequently cause these infections.
• Effective antibiotic treatment is crucial for patient recovery and preventing complications.

Purpose of the Study:

• To evaluate the efficacy and safety of fosfomycin in treating adult patients with acute bronchial and bronchopulmonary infections.
• To determine the success rate of fosfomycin therapy in a clinical setting.
• To identify the spectrum of bacteria targeted by fosfomycin in respiratory infections.

Main Methods:

• A study was conducted on 25 adult patients diagnosed with acute bronchial or bronchopulmonary processes.
• Patients received intramuscular fosfomycin at a dosage of 4 g/day for an average of 10 days.
• Sputum cultures were analyzed to identify prevalent bacterial pathogens.

Main Results:

• Fosfomycin treatment resulted in a 92% success rate, with 16 patients cured and 7 showing improvement.
• Only 2 patients (8%) experienced treatment failure.
• Streptococcus pneumoniae and Klebsiella were the most frequently isolated bacteria from sputum cultures.

Conclusions:

• Intramuscular fosfomycin demonstrates high efficacy in treating adult patients with acute bronchial and bronchopulmonary infections.
• Fosfomycin is a viable therapeutic option against common respiratory pathogens like Streptococcus pneumoniae and Klebsiella.
• The observed success rate suggests fosfomycin's significant clinical utility in managing these respiratory conditions.